VDR and metabolic dysfunction-associated steatohepatitis: LXR agonists, vitamin D receptor activators, and Hippo pathway modulators are examples of therapeutic targets that have shown promise in reducing the inflammation, fibrosis, and metabolic dysregulation linked to NASH.